← Human Trials & Peer-Reviewed Studies
Opioid modulation of the gamma-aminobutyric acid-controlled inhibition of exercise-stimulated growth hormone and prolactin secretion in normal men.
Plain-language guide to PMID 8038904 (1994): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 15 subjects.
Key Facts
- PMID
- 8038904
- Journal
- European journal of endocrinology
- Year
- 1994
- Study type
- Randomized Controlled Trial
- Authors
- Coiro V et al. (8 authors)
- DOI
- 10.1530/eje.0.1310050
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
After fasting overnight, seven subjects were tested on four mornings at least 1 week apart.
Exercise was performed on a bicycle ergometer.
Who Took Part
According to the abstract, 15 subjects were involved.
PubMed indexes the participants as adults, men only.
The possible involvement of endogenous opioids in the gamma-aminobutyric acid-controlled (GABAergic) inhibition of growth hormone (GH) and prolactin (PRL) during physical exercise was evaluated in normal men.
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
The subjects were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Some subjects received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
What Was Measured
After fasting overnight, seven subjects were tested on four mornings at least 1 week apart.
During exercise, plasma GH and PRL levels rose 5.5- and 1.9-fold, respectively.
Topics PubMed links to this paper include Analysis of Variance, Exercise, Growth Hormone, Naloxone, Prolactin, Valproic Acid and gamma-Aminobutyric Acid.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 15 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1994 (European journal of endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.